161 related articles for article (PubMed ID: 30911639)
1. Assessment of a novel mucolytic solution for dissolving mucus in pseudomyxoma peritonei: an
Pillai K; Akhter J; Morris DL
Pleura Peritoneum; 2017 Jun; 2(2):111-117. PubMed ID: 30911639
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of a novel mucolytic agent on pseudomyxoma peritonei mucin, with potential for treatment through peritoneal catheters.
Akhter J; Pillai K; Chua TC; Alzarin N; Morris DL
Am J Cancer Res; 2014; 4(5):495-507. PubMed ID: 25232491
[TBL] [Abstract][Full Text] [Related]
3. Physical and chemical characteristics of mucin secreted by pseudomyxoma peritonei (PMP).
Pillai K; Akhter J; Mekkawy A; Chua TC; Morris DL
Int J Med Sci; 2017; 14(1):18-28. PubMed ID: 28138305
[No Abstract] [Full Text] [Related]
4. A formulation for in situ lysis of mucin secreted in pseudomyxoma peritonei.
Pillai K; Akhter J; Chua TC; Morris DL
Int J Cancer; 2014 Jan; 134(2):478-86. PubMed ID: 23843173
[TBL] [Abstract][Full Text] [Related]
5. Pseudomyxoma peritonei: does a true mucolytic agent exist? In vitro and in vivo studies.
Shyr YM; Su CH; Wang HC; Lo SS; Lui WY
Am Surg; 1995 Mar; 61(3):265-70. PubMed ID: 7887544
[TBL] [Abstract][Full Text] [Related]
6. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei and Appendix Tumours.
Lansom J; Alzahrani N; Liauw W; Morris DL
Indian J Surg Oncol; 2016 Jun; 7(2):166-76. PubMed ID: 27065707
[TBL] [Abstract][Full Text] [Related]
7. Management of pseudomyxoma peritonei by cytoreduction+HIPEC (hyperthermic intraperitoneal chemotherapy): results analysis of a twelve-year experience.
Vaira M; Cioppa T; DE Marco G; Bing C; D'Amico S; D'Alessandro M; Fiorentini G; DE Simone M
In Vivo; 2009; 23(4):639-44. PubMed ID: 19567401
[TBL] [Abstract][Full Text] [Related]
8. The Biological Synthesis and the Function of Mucin 2 in Pseudomyxoma Peritonei.
Lin YL; Li Y
Cancer Manag Res; 2021; 13():7909-7917. PubMed ID: 34703312
[TBL] [Abstract][Full Text] [Related]
9. Effective Use of Bromelain and Acetylcysteine (BromAc
Skalkos E; Chen KL; Wijayawardana R; Morris DL
Anticancer Res; 2023 Oct; 43(10):4735-4738. PubMed ID: 37772592
[TBL] [Abstract][Full Text] [Related]
10. Novel Use of Bromelain and Acetylcysteine (BromAc®) for Pleural Involvement in Pseudomyxoma Peritonei.
Lam AR; Bazzi K; Valle SJ; Morris DL
Case Rep Oncol; 2021; 14(1):628-633. PubMed ID: 33976645
[TBL] [Abstract][Full Text] [Related]
11. Validation of the Recent PSOGI Pathological Classification of Pseudomyxoma Peritonei in a Single-Center Series of 265 Patients Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
Baratti D; Kusamura S; Milione M; Bruno F; Guaglio M; Deraco M
Ann Surg Oncol; 2018 Feb; 25(2):404-413. PubMed ID: 29159742
[TBL] [Abstract][Full Text] [Related]
12. Pre- and post-operative antibiotics in conjunction with cytoreductive surgery and heated intraperitoneal chemotherapy (HIPEC) should be considered for pseudomyxoma peritonei (PMP) treatment.
Merrell DS; McAvoy TJ; King MC; Sittig M; Millar EV; Nieroda C; Metcalf JL; Blum FC; Testerman TL; Sardi A
Eur J Surg Oncol; 2019 Sep; 45(9):1723-1726. PubMed ID: 30770164
[TBL] [Abstract][Full Text] [Related]
13. Mucolysis by ascorbic acid and hydrogen peroxide on compact mucin secreted in pseudomyxoma peritonei.
Pillai K; Akhter J; Chua TC; Morris DL
J Surg Res; 2012 May; 174(2):e69-73. PubMed ID: 22261589
[TBL] [Abstract][Full Text] [Related]
14. Acidic glycosaminoglycans of abdominal mucin in a case of pseudomyxoma peritonei caused by appendiceal cancer.
Miyashita T; Murata K; Hoshino E; Nishiya H; Ono Y; Akaoka I; Kunii O
Dig Dis Sci; 1999 Nov; 44(11):2231-4. PubMed ID: 10573367
[TBL] [Abstract][Full Text] [Related]
15. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in pseudomyxoma peritonei of appendiceal origin: result of a single centre study.
Di Leo A; Corvasce A; Weindelmayer J; Mason EJ; Casella F; de Manzoni G
Updates Surg; 2020 Dec; 72(4):1207-1212. PubMed ID: 32410159
[TBL] [Abstract][Full Text] [Related]
16. Pseudomyxoma Peritonei: A Case Report of a 62-Year-Old Female With Unexplained Abdominal Enlargement and Appendiceal Origin.
Mohfouz A; Hamed M; Patel A; Tasnim S; Shah P
Cureus; 2022 Feb; 14(2):e22255. PubMed ID: 35340503
[TBL] [Abstract][Full Text] [Related]
17. Complete pathological response of high grade appendicular neoplasm induced Pseudomyxoma Peritonei (PMP) after neoadjuvant intra-peritoneal chemotherapy: A case report.
Padmanabhan N; Ishibashi H; Nishihara K; Sako S; Katayama K; Wakama S; Kamada Y; Yonemura Y
Int J Surg Case Rep; 2020; 72():117-121. PubMed ID: 32534414
[TBL] [Abstract][Full Text] [Related]
18. Intraoperative oxygen tension and redox homeostasis in Pseudomyxoma peritonei: A short case series.
Valenzuela-Molina F; Bura FI; Vázquez-Borrego MC; Granados-Rodríguez M; Rufián-Andujar B; Rufián-Peña S; Casado-Adam Á; Sánchez-Hidalgo JM; Rodríguez-Ortiz L; Ortega-Salas R; Martínez-López A; Michán C; Alhama J; Arjona-Sánchez Á; Romero-Ruiz A
Front Oncol; 2023; 13():1076500. PubMed ID: 36776312
[TBL] [Abstract][Full Text] [Related]
19. Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei Arising from Urachus.
Liu Y; Ishibashi H; Hirano M; Takeshita K; Mizumoto A; Ichinose M; Nishino E; Kashu I; Yamamoto Y; Sugarbaker PH; Yonemura Y
Ann Surg Oncol; 2015 Aug; 22(8):2799-805. PubMed ID: 25572681
[TBL] [Abstract][Full Text] [Related]
20. Impact of Cellularity on Oncologic Outcomes Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Pseudomyxoma Peritonei.
Choudry HA; Pai RK; Shuai Y; Ramalingam L; Jones HL; Pingpank JF; Ahrendt SS; Holtzman MP; Zureikat AH; Zeh HJ; Bartlett DL
Ann Surg Oncol; 2018 Jan; 25(1):76-82. PubMed ID: 29110275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
